Nixon Peabody Trust Co. Has $17.37 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Nixon Peabody Trust Co. reduced its position in Johnson & Johnson (NYSE:JNJ) by 1.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 107,187 shares of the company’s stock after selling 1,315 shares during the quarter. Johnson & Johnson makes up about 1.4% of Nixon Peabody Trust Co.’s holdings, making the stock its 22nd largest holding. Nixon Peabody Trust Co.’s holdings in Johnson & Johnson were worth $17,371,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Meeder Advisory Services Inc. increased its stake in shares of Johnson & Johnson by 1.1% during the 3rd quarter. Meeder Advisory Services Inc. now owns 36,477 shares of the company’s stock worth $5,911,000 after purchasing an additional 401 shares during the last quarter. MidAtlantic Capital Management Inc. acquired a new position in Johnson & Johnson during the third quarter worth $56,000. Cassaday & Co Wealth Management LLC raised its holdings in Johnson & Johnson by 1.0% during the third quarter. Cassaday & Co Wealth Management LLC now owns 33,780 shares of the company’s stock valued at $5,474,000 after buying an additional 340 shares in the last quarter. Drive Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.7% in the third quarter. Drive Wealth Management LLC now owns 10,081 shares of the company’s stock worth $1,634,000 after buying an additional 168 shares during the last quarter. Finally, First Western Trust Bank increased its holdings in shares of Johnson & Johnson by 1.1% during the 3rd quarter. First Western Trust Bank now owns 19,636 shares of the company’s stock valued at $3,182,000 after acquiring an additional 214 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JNJ. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Wolfe Research started coverage on Johnson & Johnson in a research note on Friday. They issued an “outperform” rating and a $190.00 target price for the company. Guggenheim upped their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Finally, Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $175.94.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $0.68 on Monday, reaching $154.68. 345,482 shares of the company’s stock were exchanged, compared to its average volume of 6,987,340. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a fifty day moving average of $161.35 and a 200-day moving average of $156.13. The company has a market capitalization of $372.41 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the business posted $2.66 earnings per share. On average, research analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.21%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.